Mersana Therapeutics (MRSN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

MRSN Mersana Therapeutics

Watchlist

0.528
-0.029-5.21%

Close Feb 25 16:00 ET

0.477
-0.051-9.65%

Pre 04:45 ET

65.18MMarket Cap-0.88P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Earnings Preview: MRSN to Report Financial Results Pre-market on March 03
Moomoo News20:00 ET
Mersana Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswireFeb 25 08:00 ET
Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025
GlobeNewswireFeb 24 16:01 ET
TD Cowen Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
Moomoo NewsFeb 10 07:31 ET · Ratings
Mersana Therapeutics (MRSN) Receives a Buy From TD Cowen
TipRanksFeb 10 07:16 ET · Ratings
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswireFeb 7 16:05 ET

Comments

Teddy123

Jan 30 07:22

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

$Mersana Therapeutics (MRSN.US)$
What is Mersana Therapeutics' (MRSN) main focus in cancer treatment?
Mersana Therapeutics focuses on discovering and developing antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need.
Exclusive: Mersana Therapeutics CEO to Reveal ADC Pipeline Updates at Guggenheim Conference

WeiTheSaint469

Jan 24 14:45

lfg

$Mersana Therapeutics (MRSN.US)$

Wins333

Jan 24 12:35

$Mersana Therapeutics (MRSN.US)$ this is the way

Teddy123

Jan 22 06:42

MRSN stock touches 52-week low at $0.56 amid market challenges

$Mersana Therapeutics (MRSN.US)$
Citi recently initiated coverage on Mersana Therapeutics with a Buy rating, spotlighting the potential of the company's XMT-1660 project. The firm's coverage transfer to analyst Yigal Nochomovitz comes with optimistic expectations for the XMT-1660 data. This upcoming data is seen as a significant catalyst that could revitalize interest in the company's shares.
On the clinical front, Mersana's XMT-1660 h...